{{Rsnum
|rsid=2024115
|Gene=HTT
|Chromosome=4
|position=3102841
|Orientation=minus
|GMAF=0.4027
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=HTT
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 15.0 | 45.1 | 39.8
| HCB | 16.8 | 46.7 | 36.5
| JPT | 13.3 | 54.9 | 31.9
| YRI | 20.5 | 43.8 | 35.6
| ASW | 12.3 | 47.4 | 40.4
| CHB | 16.8 | 46.7 | 36.5
| CHD | 20.2 | 47.7 | 32.1
| GIH | 7.0 | 31.0 | 62.0
| LWK | 19.1 | 51.8 | 29.1
| MEX | 13.8 | 51.7 | 34.5
| MKK | 21.2 | 49.4 | 29.5
| TSI | 10.9 | 49.5 | 39.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2024115
|Name_s=
|Gene_s=HTT
|Feature=
|Evidence=PubMed ID:19249009
|Annotation=This SNP is part of a haplogroup found to be associated with CAG repeat number expansion in Huntington disease (36 or more CAG repeats) in Europeans and also with intermediate expansion(27-35 repeats) in unaffected individuals(Europeans). This SNP itself was significantly associated(p < 0.0023) with the expansion.
|Drugs=
|Drug Classes=
|Diseases=Huntington Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA164918141
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2024115
|overall_frequency_n=55
|overall_frequency_d=128
|overall_frequency=0.429688
|n_genomes=32
|n_genomes_annotated=0
|n_haplomes=42
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}